Outlook Therapeutics director buys 95,398 shares

Outlook Therapeutics director Faisal Ghiath Sukhtian purchased 95,398 shares of common stock on July 29, 2026 at 1.0482 per share in an open-market or private transaction.

Rhea-AI Filing Summary

Outlook Therapeutics director Faisal Ghiath Sukhtian purchased 95,398 shares of common stock on July 29, 2026 at 1.0482 per share in an open-market or private transaction. After this buy, he directly owns 220,972 common shares. The transaction was not reported as made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 95,398 shares

Net Buy 1 txn

Insider Sukhtian Faisal Ghiath

Role Director

Bought 95,398 shs ($100K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	95,398	$1.0482	$100K

Holdings After Transaction: Common Stock — 220,972 shares (Direct)

Key Figures

Shares purchased: 95,398 shares Purchase price: 1.0482 per share Shares owned after transaction: 220,972 shares +1 more

4 metrics

Shares purchased 95,398 shares Common Stock acquired on 2026-07-29 in a non-derivative transaction

Purchase price 1.0482 per share Per-share price for the 95,398 common shares bought

Shares owned after transaction 220,972 shares Director’s direct common stock holdings following the reported purchase

Net shares bought 95,398 shares Net common shares acquired across all transactions in this Form 4

Key Terms

Form 4, non-derivative, open market or private transaction

3 terms

Form 4 regulatory

"Insider transaction reported on SEC Form 4 for Outlook Therapeutics, Inc."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"The transaction_type is listed as "non-derivative" for the Common Stock purchase."

open market or private transaction financial

"The code description states "Purchase in open market or private transaction"."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Outlook Therapeutics (OTLK) disclose in this Form 4?

Outlook Therapeutics disclosed that director Faisal Ghiath Sukhtian bought 95,398 common shares. The purchase occurred on July 29, 2026 at a price of 1.0482 per share in an open-market or private transaction.

At what price did the Outlook Therapeutics (OTLK) director buy shares?

The director’s purchase was executed at 1.0482 per share. This price applies to the 95,398 common shares acquired on July 29, 2026, reported as a non-derivative open-market or private transaction on Form 4.

How many Outlook Therapeutics (OTLK) shares does the director own after the transaction?

Following the reported purchase, director Faisal Ghiath Sukhtian directly owns 220,972 common shares. This post-transaction holding reflects the addition of 95,398 shares acquired on July 29, 2026 in a non-derivative transaction.

Was the Outlook Therapeutics (OTLK) insider trade under a Rule 10b5-1 plan?

The filing indicates the transaction was not made under a Rule 10b5-1 trading plan. The document-level 10b5-1 checkbox is marked false, so the July 29, 2026 purchase is not reported as pre-arranged under such a plan.

What type of security did the Outlook Therapeutics (OTLK) director purchase?

The director purchased Common Stock of Outlook Therapeutics in a non-derivative transaction. The Form 4 shows 95,398 common shares acquired directly, with total direct ownership rising to 220,972 common shares after the purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/29/2026 - 03:19 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sukhtian Faisal Ghiath

(Last) (First) (Middle)

C/O OUTLOOK THERAPEUTICS, INC.

111 S. WOOD AVE, UNIT #100

(Street)

ISELIN NEW JERSEY 08830

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/29/2026		P		95,398	A	$1.0482	220,972	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Lawrence Kenyon, Attorney-in-Fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)